Skip to main content

Table 2 Hazard ratios for reaching remission/low disease activity and individual components in RA patients associated with overlapping SS

From: Overlapping Sjogren’s syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019

 Unmatched cohort (n = 1099)Matched cohort (n = 252)Trimmed cohort (n = 242)
Remission based on composite disease activity score
 DAS28-ESR0.68 (0.62, 0.75)0.71 (0.62, 0.82)0.74 (0.64, 0.85)
 DAS28-CRP0.80 (0.74, 0.87)0.74 (0.66, 0.83)0.74 (0.66, 0.83)
 SDAI0.82 (0.74, 0.91)0.82 (0.70, 0.94)0.83 (0.72, 0.97)
 CDAI0.77 (0.70, 0.86)0.78 (0.67, 0.91)0.78 (0.67, 0.91)
 Boolean0.83 (0.75, 0.92)0.80 (0.69, 0.93)0.82 (0.70, 0.95)
Remission/LDA based on composite disease activity score
 DAS28-ESR0.76 (0.70, 0.82)0.73 (0.65, 0.82)0.74 (0.66, 0.83)
 DAS28-CRP0.80 (0.74, 0.86)0.76 (0.68, 0.84)0.75 (0.68, 0.84)
 SDAI0.79 (0.73, 0.85)0.74 (0.66, 0.82)0.74 (0.66, 0.82)
 CDAI0.78 (0.73, 0.84)0.74 (0.66, 0.82)0.74 (0.66, 0.82)
Individual components of disease activity score
 28SJC ≤ 10.83 (0.77, 0.89)0.77 (0.69, 0.85)0.76 (0.68, 0.84)
 28TJC ≤ 10.81 (0.75, 0.87)0.79 (0.70, 0.88)0.78 (0.70, 0.88)
 PtGA ≤ 10.81 (0.74, 0.89)0.82 (0.71, 0.94)0.82 (0.72, 0.95)
 EGA ≤ 10.81 (0.74, 0.88)0.78 (0.69, 0.88)0.79 (0.70, 0.89)
 ESR ≤ ULN0.66 (0.61, 0.73)0.69 (0.61, 0.79)0.74 (0.65, 0.84)
 CRP ≤ 1 mg/dL0.84 (0.78, 0.90)0.76 (0.68, 0.84)0.77 (0.69, 0.85)
  1. Values are presented as hazard ratio (95% CI) for reaching remission and/or low disease activity based on DAS28-ESR, DAS28-CRP, SDAI, CDAI, and main components in RA patients. Unmatched cohort refers to whole sample (n = 1099); matched cohort refers to propensity score matched (PSM) patients (n = 252) after correcting gender, age, RA duration, RF/ACPA status, DAS28-CRP at 1st visit, and T2T or not; trimmed cohort refers to cohort with either trimmed at the 5th–95th percentiles of the PSM (n = 242). ULN of ESR refers to 15 mm/h for male and 20 mm/h for female